Dipl.-Ing. Dr. Alina Nussbaumer-Pröll, BSc.
Department of Clinical Pharmacology
Position: Research Associate (Postdoc)
ORCID: ORCID 0000-0002-8238-8488
alina.nussbaumer-proell@meduniwien.ac.at
Keywords
Pharmacokinetics
Research group(s)
- Section of Clinical Pharmacokinetics / Pharmacogenetics and Imaging
Head: Markus Zeitlinger
Research Area: Our main focus is the study of the drug distribution process by employing techniques to measure target site distribution directly, i.e. PET or microdialysis.
Members:
Research interests
My focus lies on in-vitro pharmacokinetic and pharmacodynamic studies with a Hollow Fiber Infection Model (HFIM) supported by standard practice methods for antibiotic susceptibility testing.
Techniques, methods & infrastructure
- Hollow Fiber Infection Model
- Minimal Inhibitory Concentration determinations (broth micro/macro-dilution, agar diffusion assays, E-Test etc.)
- Time Kill Curves
Selected publications
- Nussbaumer-Pröll, A. et al. (2022) ‘Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa’, Frontiers in Pharmacology, 13. Available at: http://dx.doi.org/10.3389/fphar.2022.840692.
- Nussbaumer-Pröll, A.K. et al. (2022) ‘Comparison of Antimycotic Activity of Originator and Generics of Voriconazole and Anidulafungin against Clinical Isolates of Candida albicans and Candida glabrata’, Journal of Fungi, 8(2), p. 195. Available at: http://dx.doi.org/10.3390/jof8020195.
- Nussbaumer-Pröll, A. and Zeitlinger, M. (2020) ‘Use of Supplemented or Human Material to Simulate PD Behavior of Antibiotics at the Target Site In Vitro’, Pharmaceutics, 12(8), p. 773. Available at: http://dx.doi.org/10.3390/pharmaceutics12080773.
- Nussbaumer-Pröll, A.K. et al. (2019) ‘Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics’, European Journal of Clinical Microbiology & Infectious Diseases, 38(3), pp. 485–495. Available at: http://dx.doi.org/10.1007/s10096-018-03452-4.
- Nussbaumer-Pröll, A.K. et al. (2019) ‘Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections’, Journal of Antimicrobial Chemotherapy, 75(3), pp. 593–599. Available at: http://dx.doi.org/10.1093/jac/dkz488.